A more detailed discussion of Westaim's 2008 first quarter results can
be found at http://www.westaim.com and http://www.sedar.com.
THE WESTAIM CORPORATION
Financial Highlights
(unaudited)
(thousands of dollars except per share data)
-------------------------------------------------------------------------
Three Months Ended March 31
--------------------------------
Consolidated Statements of Operations 2008 2007
-------------------------------------------------------------------------
Revenue $ 5,209 $ 6,131
Income from continuing operations 3,227 1,899
Net loss (6,857) (6,700)
Net income (loss) per common share -
basic and diluted
Continuing operations 0.03 0.02
Net loss (0.07) (0.07)
Weighted average number of common
shares outstanding (thousands) 94,186 93,992
-------------------------------------------------------------------------
Three Months Ended March 31
--------------------------------
Segmented Information 2008 2007
-------------------------------------------------------------------------
Revenue from continuing operations
Nucryst Pharmaceuticals $ 5,209 $ 6,131
---------------------------------------------------------------------
'/>"/>
| SOURCE Westaim Corporation Copyright©2008 PR Newswire. All rights reserved |